New hope for advanced cancer patients in early drug trial
NCT ID NCT06937957
Summary
This is the first human study of an experimental cancer drug called BR111. The main goal is to find a safe dose and see how the body handles the drug in 166 patients with advanced solid tumors or lymphoma who have run out of standard treatment options. Researchers will also check if the drug shows any early signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Cancer
RECRUITINGShanghai, Pudong New Area, No. 4333, Kangxin Road, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.